Samantha I. Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Samantha I. Liang has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Enjun Yang
Parker Institute for Cancer Immunotherapy, San Francisco, California, USA
21 shared publications - Zoe Quandt
UCSF 5 Division of Endocrinology San Francisco, California
21 shared publications - Carin R. Espenschied
Guardant Health, Inc Palo Alto California USA
20 shared publications - Jing Wang
Guardant Health, Palo Alto, California
20 shared publications - John E. Connolly
Parker Institute for Cancer Immunotherapy, San Francisco, California
20 shared publications - Jude Masannat
Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida
20 shared publications
Latest Publications
- Open Access
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Methylation TF Results by Timepoint
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Methylation TF Results by Timepoint
- Open Access
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Forest Plot analysis for percentage TF change threshold determination
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Forest Plot analysis for percentage TF change threshold determination
- Open Access
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Supplementary Figure S2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Supplementary Figure S2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
- Open Access
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Strobe diagram showing inclusion and exclusion for patient samples from the RADIOHEAD study in which successful samples passed all QC metrics and delivered a TF result. Chemo, chemotherapy.
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Strobe diagram showing inclusion and exclusion for patient samples from the RADIOHEAD study in which successful samples passed all QC metrics and delivered a TF result. Chemo, chemotherapy.
- Open Access
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
A–D, Longitudinal assessment of TF predicts ICI benefit in a pan-solid tumor cohort (n = 521; patients in whom rwPFS or rwOS event occurred before the reindex date were excluded where indicated). A, Kaplan–Meier analysis comparing the rwPFS of MR at any timepoint [NR (95% CI, NR–NR)] vs. nMR at all timepoints [3.93 months (95% CI, 3.33–4.40); n = 513]. B, Forest plot for CPH model for rwPFS with a HR of 0.24 (0.19–0.315) for MR vs. nMR (n = 513). C, Kaplan–Meier analysis comparing the rwOS of MR at any timepoint vs. nMR at all timepoints [NR (95% CI, NR–NR) vs. 7.166 months (95% CI, 5.73–9.10; n = 520)]. D, Forest plot for CPH model for rwOS with a HR of 0.28 (0.21, 0.38) for MR vs. nMR (n = 520).
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
A–D, Longitudinal assessment of TF predicts ICI benefit in a pan-solid tumor cohort (n = 521; patients in whom rwPFS or rwOS event occurred before the reindex date were excluded where indicated). A, Kaplan–Meier analysis comparing the rwPFS of MR at any timepoint [NR (95% CI, NR–NR)] vs. nMR at all timepoints [3.93 months (95% CI, 3.33–4.40); n = 513]. B, Forest plot for CPH model for rwPFS with a HR of 0.24 (0.19–0.315) for MR vs. nMR (n = 513). C, Kaplan–Meier analysis comparing the rwOS of MR at any timepoint vs. nMR at all timepoints [NR (95% CI, NR–NR) vs. 7.166 months (95% CI, 5.73–9.10; n = 520)]. D, Forest plot for CPH model for rwOS with a HR of 0.28 (0.21, 0.38) for MR vs. nMR (n = 520).
- Open Access
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
A and B, Candidate thresholds for TF change indicating MR and nMR among the patients in whom either T0 or T1 were quantifiable (n = 459). A, Forest plot for various TF changes (B) Kaplan–Meier analysis of rwPFS by select candidate thresholds across the full dataset. Log-rank test between groups: 100% vs. any decrease, P < 0.005; 80% decrease vs. any decrease, P = 0.01; 100% decrease vs. 80% decrease, P = 0.04; 100% decrease vs. any increase, P < 0.005; 80% decrease vs. any increase, P < 0.005; any decrease vs any increase, P < 0.005. c-index, concordance index.
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
A and B, Candidate thresholds for TF change indicating MR and nMR among the patients in whom either T0 or T1 were quantifiable (n = 459). A, Forest plot for various TF changes (B) Kaplan–Meier analysis of rwPFS by select candidate thresholds across the full dataset. Log-rank test between groups: 100% vs. any decrease, P < 0.005; 80% decrease vs. any decrease, P = 0.01; 100% decrease vs. 80% decrease, P = 0.04; 100% decrease vs. any increase, P < 0.005; 80% decrease vs. any increase, P < 0.005; any decrease vs any increase, P < 0.005. c-index, concordance index.
- Open Access
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Sensitivity analysis used to demonstrate impact of time ranges on longitudinal monitoring analysis
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Sensitivity analysis used to demonstrate impact of time ranges on longitudinal monitoring analysis
- Open Access
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Real-world outcomes of patients with TF below LOQ at both timepoints
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Real-world outcomes of patients with TF below LOQ at both timepoints
- Open Access
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Successful samples by cancer type and timepoint
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Successful samples by cancer type and timepoint
- Open Access
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
A–F, Representative patient examples demonstrating serial monitoring of TF for patients with (A) CR with head and neck squamous cell carcinoma; rwPFS = 15 months. B, SD with NSCLC; rwPFS = 13.77 months. C, SD with endometrial carcinoma; rwPFS = 12.37 months. D, PD with hepatocellular cancer; rwPFS = 5.6 months. E, PD with SCLC; rwPFS = 6.233 months. F, PD with NSCLC; rwPFS = 6.07 months; notably, TF was not detected at baseline.
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
A–F, Representative patient examples demonstrating serial monitoring of TF for patients with (A) CR with head and neck squamous cell carcinoma; rwPFS = 15 months. B, SD with NSCLC; rwPFS = 13.77 months. C, SD with endometrial carcinoma; rwPFS = 12.37 months. D, PD with hepatocellular cancer; rwPFS = 5.6 months. E, PD with SCLC; rwPFS = 6.233 months. F, PD with NSCLC; rwPFS = 6.07 months; notably, TF was not detected at baseline.